CTLA4 and melanoma: This information for samples from a cohort of 30 melanoma patients is paired with the response (responder or nonresponder, determined by immune-related response criteria or irRC (28)) to immune checkpoint inhibitors (ICIs) involving anti-PD1, anti-CTLA4, or the combination of the two (Fig. 1a) (5, 28).